HEBERSaVax (also known as CIGB-247 in earlier preclinical publications) represents a novel active immunotherapy platform targeting vascular endothelial growth factor (VEGF), a pivotal tumor angiogenesis and immune suppression regulator. This evidence concerns the gene VEGFA and neoplasm.